A £500,000 ($650,000) investment by the National Health Service of England will expand a clinical trial in that country of the Personal KinetiGraph, or PKG smartwatch, a wrist-worn device that can detect abnormal movements in people with Parkinson’s disease. PKG, developed by Global Kinetics and approved by the U.S. Food…
News
Lucy Therapeutics (LucyTx) has received a $4.9 million, two-year grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance work in the company’s mitochondrial platform that could lead to new Parkinson’s disease treatments. The award includes access to a network of MJFF staff and relevant foundation…
Electrical implants in the spine can clear up feelings of lightheadedness upon standing — the result of a condition called orthostatic hypotension — in people with neurological disorders like Parkinson’s disease, new research shows. Orthostatic hypotension refers to a sudden drop in blood pressure when a person moves from…
Diabetes and high blood sugar were associated with elevated levels of neurofilament light (NfL) — a biomarker of nerve cell damage — and worse cognitive function among people with Parkinson’s disease, according to a recent study. “Our study is the first to show that diabetes and [a measure of…
The Michael J. Fox Foundation (MJFF) has named Brit Mollenhauer, MD, a foundation scientific advisor, as the winner of this year’s J. William Langston Award in recognition of her contributions to Parkinson’s research in expanding avenues to new treatments. Mollenhauer’s work has focused on developing…
Gb Sciences is initiating a dose-ranging study of its investigational cannabinoid-based formulations in a rodent model of Parkinson’s disease next month as a step toward a first-in-human study. The study will determine the dose range of active ingredients to be used in human trials and potential side effects.
Treatment with GT-02287, an experimental oral therapy for Parkinson’s disease, corrected numerous damaging abnormalities associated with Parkinson’s in cell models, according to new data shared at a recent conference. “The data we presented at the Synuclein Meeting demonstrates further encouraging disease modifying potential for patients with Parkinson’s disease who currently…
Practicing tai chi for a year improved gait and balance in early-stage Parkinson’s disease patients, improving both inflammation and metabolism as well as brain function, according to a recent study. The study, “Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients,” was published…
Asceneuron’s experimental oral therapy ASN90 was found to significantly reduce the levels of toxic clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease — and improve motor function in a mouse model of the disease. The molecule — a suppressor of O–GlcNAcase (OGA), an enzyme involved…
During Parkinson’s Awareness Month, Aspen Neuroscience will launch a patient screening study to potentially advance ANPD001, its experimental, personalized neuron replacement therapy for Parkinson’s disease, into clinical trials. Considered to be the first of its kind, the Trial-Ready Cohort Study will involve several screening sites in the U.S.
Recent Posts
- Fecal transplants ease motor symptoms in early Parkinson’s: Study
- ‘Moving Day, A Walk for Parkinson’s’ marks 15th year with events across US
- Choosing when to share a Parkinson’s diagnosis isn’t one-size-fits-all
- Parkinson’s Awareness Month to focus on education, finding real answers
- Our solution for staying on top of my husband’s Parkinson’s medications